Akero Therapeutics, Inc. (AKRO)
- Previous Close
18.93 - Open
19.18 - Bid 19.48 x 100
- Ask 19.68 x 100
- Day's Range
18.96 - 19.65 - 52 Week Range
11.25 - 58.38 - Volume
209,140 - Avg. Volume
1,400,512 - Market Cap (intraday)
1.353B - Beta (5Y Monthly) -0.38
- PE Ratio (TTM)
-- - EPS (TTM)
-2.89 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
48.38
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
akerotx.comRecent News: AKRO
Performance Overview: AKRO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AKRO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AKRO
Valuation Measures
Market Cap
1.31B
Enterprise Value
781.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.26
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.07%
Return on Equity (ttm)
-35.22%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-151.76M
Diluted EPS (ttm)
-2.89
Balance Sheet and Cash Flow
Total Cash (mrq)
550.01M
Total Debt/Equity (mrq)
4.86%
Levered Free Cash Flow (ttm)
-93.79M